Gustave Roussy Cancer Campus, Villejuif, Cedex, France.
INSERM U1015, Villejuif, France.
Adv Exp Med Biol. 2017;1036:65-79. doi: 10.1007/978-3-319-67577-0_5.
The host immune system is continuously exposed to dying cells and has evolved to distinguish between cell death events signaling potential threats and physiological apoptosis that should be tolerated. Tumors can use this distinction to their advantage, promoting apoptotic death of cancer cells to induce tolerance and evasion of immunosurveillance. On the other hand, stimuli that cause immunogenic death of cancer cells can induce an effective anti-tumor immune response. In this chapter we discuss different forms of cell death in the tumor microenvironment, and how these interact with host immune cells to impact tumor progression and cancer therapy. We focus on how cancer cells hijack aspects of cell death to promote tumor survival, and how anti-cancer treatments that activate immunogenic death modalities give strong and durable clinical efficacy.
宿主免疫系统不断暴露于死亡细胞中,并进化出区分潜在威胁的细胞死亡事件和应被耐受的生理性细胞凋亡的能力。肿瘤可以利用这种区别来获得优势,促进癌细胞的凋亡死亡以诱导耐受和逃避免疫监视。另一方面,诱导癌细胞发生免疫原性死亡的刺激可以引发有效的抗肿瘤免疫反应。在本章中,我们讨论了肿瘤微环境中不同形式的细胞死亡,以及这些细胞死亡如何与宿主免疫细胞相互作用,影响肿瘤进展和癌症治疗。我们重点讨论了癌细胞如何劫持细胞死亡的各个方面来促进肿瘤的存活,以及激活免疫原性细胞死亡模式的抗癌治疗如何产生强大而持久的临床疗效。